NasdaqCM - Nasdaq Real Time Price • USD
Aligos Therapeutics, Inc. (ALGS)
As of 9:45 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.16 | -0.17 | -0.73 | -0.71 |
| Low Estimate | -0.16 | -0.17 | -0.73 | -0.71 |
| High Estimate | -0.16 | -0.17 | -0.73 | -0.71 |
| Year Ago EPS | -0.43 | -0.41 | -1.36 | -0.73 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | 990k | -- |
| Low Estimate | -- | -- | 990k | -- |
| High Estimate | -- | -- | 990k | -- |
| Year Ago Sales | 6.89M | 2.5M | 9.34M | 990k |
| Sales Growth (year/est) | -- | -- | -89.40% | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.49 | -0.47 | -0.27 | -0.19 |
| EPS Actual | -0.43 | -0.41 | -0.22 | -0.22 |
| Difference | 0.06 | 0.06 | 0.05 | -0.03 |
| Surprise % | 12.20% | 12.80% | 18.50% | -15.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.16 | -0.17 | -0.73 | -0.71 |
| 7 Days Ago | -0.16 | -0.17 | -0.74 | -0.63 |
| 30 Days Ago | -0.21 | -0.21 | -0.83 | -0.82 |
| 60 Days Ago | -0.21 | -0.21 | -0.83 | -0.82 |
| 90 Days Ago | -0.26 | -0.25 | -1.04 | -1.06 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ALGS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 62.80% | -- | -- | 8.90% |
| Next Qtr. | 58.50% | -- | -- | 11.40% |
| Current Year | 46.30% | -- | -- | 5.70% |
| Next Year | 2.70% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.43% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Piper Sandler: Overweight | 1/17/2023 |
| Upgrade | Piper Sandler: Neutral to Overweight | 1/6/2023 |
| Upgrade | Jefferies: Hold to Buy | 1/6/2023 |
| Maintains | SVB Leerink: Market Perform | 11/3/2022 |
| Downgrade | SVB Leerink: Outperform to Market Perform | 5/5/2022 |
| Maintains | SVB Leerink: Outperform | 3/23/2022 |
Related Tickers
ASMB Assembly Biosciences, Inc.
15.51
-1.51%
GLTO Galecto, Inc.
0.5496
+1.90%
AVRO AVROBIO, Inc.
1.4700
+0.68%
SPRO Spero Therapeutics, Inc.
1.4300
-1.36%
ACHL Achilles Therapeutics plc
0.9398
+4.41%
NERV Minerva Neurosciences, Inc.
3.3400
-0.59%
SPRB Spruce Biosciences, Inc.
0.6754
+0.21%
IKNA Ikena Oncology, Inc.
1.7301
-1.70%
CLRB Cellectar Biosciences, Inc.
3.1000
+2.31%
CTMX CytomX Therapeutics, Inc.
1.6400
-1.80%